1. Home
  2. RBBN vs FULC Comparison

RBBN vs FULC Comparison

Compare RBBN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$2.22

Market Cap

493.4M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

BUY

Current Price

$3.74

Market Cap

467.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
RBBN
FULC
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.4M
467.8M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
RBBN
FULC
Price
$2.22
$3.74
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$4.67
$16.38
AVG Volume (30 Days)
826.2K
5.3M
Earning Date
04-28-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$2.83
52 Week High
$4.29
$15.74

Technical Indicators

Market Signals
Indicator
RBBN
FULC
Relative Strength Index (RSI) 31.81 36.12
Support Level $2.05 $2.83
Resistance Level $2.27 $8.34
Average True Range (ATR) 0.14 0.23
MACD -0.06 0.14
Stochastic Oscillator 12.57 54.81

Price Performance

Historical Comparison
RBBN
FULC

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: